ImmunityBio (IBRX) Short Interest Ratio & Short Volume → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IBRX Stock Alerts $4.94 -0.33 (-6.26%) (As of 04/22/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media ImmunityBio Short Interest DataCurrent Short Volume54,770,000 sharesPrevious Short Volume53,250,000 sharesChange Vs. Previous Month+2.85%Dollar Volume Sold Short$294.11 millionShort Interest Ratio / Days to Cover13.6Last Record DateMarch 31, 2024Outstanding Shares677,003,000 sharesFloat Size131,910,000 sharesShort Percent of Float41.52%Today's Trading Volume4,362,528 sharesAverage Trading Volume4,029,374 sharesToday's Volume Vs. Average108% Short Selling ImmunityBio ? Sign up to receive the latest short interest report for ImmunityBio and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIBRX Short Interest Over TimeIBRX Days to Cover Over TimeIBRX Percentage of Float Shorted Over Time Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… ImmunityBio Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202454,770,000 shares $294.11 million +2.9%41.5%13.6 $5.37 3/15/202453,250,000 shares $273.17 million +3.3%40.4%13.3 $5.13 2/29/202451,550,000 shares $243.83 million +9.4%39.4%12.2 $4.73 2/15/202447,140,000 shares $225.33 million +7.3%36.1%11.4 $4.78 1/31/202443,930,000 shares $147.60 million +4.8%33.6%10.5 $3.36 1/15/202441,930,000 shares $161.43 million +3.5%32.1%6.8 $3.85 Get the Latest News and Ratings for IBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. 12/31/202340,520,000 shares $203.41 million +7.1%31.0%6.8 $5.02 12/15/202337,840,000 shares $162.71 million +4.7%N/A6.5 $4.30 11/30/202336,140,000 shares $133.00 million +1.4%N/A6.6 $3.68 11/15/202335,660,000 shares $145.85 million -14.9%N/A6.7 $4.09 10/31/202341,920,000 shares $131.63 million +0.7%N/A8.7 $3.14 10/15/202341,640,000 shares $54.55 million +5.3%N/A13.7 $1.31 9/30/202339,540,000 shares $66.82 million +8.5%30.2%14.6 $1.69 9/15/202336,440,000 shares $65.59 million +36.4%19.8%14.1 $1.80 8/31/202326,720,000 shares $43.02 million +17.4%23.5%10.7 $1.61 8/15/202322,760,000 shares $44.61 million -4.8%20.0%8.8 $1.96 7/31/202323,900,000 shares $52.58 million -0.8%22.0%6.1 $2.20 7/15/202324,100,000 shares $67.00 million +3.5%22.2%5.3 $2.78 6/30/202323,290,000 shares $64.75 million -0.6%21.5%4.8 $2.78 6/15/202323,440,000 shares $65.40 million +4.7%21.6%4.6 $2.79 5/31/202322,390,000 shares $61.57 million -10.3%20.7%3.8 $2.75 5/15/202324,960,000 shares $80.37 million -16.7%23.0%4.2 $3.22 4/30/202329,980,000 shares $83.94 million +12.6%27.6%6 $2.80 4/15/202326,630,000 shares $51.40 million -0.4%24.6%6.7 $1.93 3/31/202326,730,000 shares $48.65 million +4.7%30.7%7.7 $1.82 3/15/202325,520,000 shares $36.49 million +11.7%29.3%8.1 $1.43 2/28/202322,850,000 shares $55.75 million -3.8%26.2%10.1 $2.44 2/15/202323,760,000 shares $83.16 million -1.1%29.0%12.3 $3.50 1/31/202324,030,000 shares $91.31 million +6.2%29.3%14 $3.80 1/15/202322,630,000 shares $108.17 million +0.9%27.6%14.1 $4.78 12/30/202222,430,000 shares $113.72 million -5.5%30.1%14.5 $5.07 12/15/202223,730,000 shares $159.23 million -0.4%31.8%15.8 $6.71 11/30/202223,830,000 shares $131.30 million -1.0%28.8%13.3 $5.51 11/15/202224,080,000 shares $145.68 million +1.5%29.1%14 $6.05 10/31/202223,730,000 shares $130.52 million +1.0%28.6%14.6 $5.50 10/15/202223,490,000 shares $116.04 million -5.0%28.4%14.6 $4.94 9/30/202224,720,000 shares $122.86 million +13.6%29.8%15.6 $4.97 9/15/202221,770,000 shares $139.98 million +7.8%26.3%13.5 $6.43 8/31/202220,190,000 shares $80.76 million +6.5%24.9%13.6 $4.00 8/15/202218,950,000 shares $89.63 million +1.5%23.4%11.1 $4.73top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… IBRX Short Interest - Frequently Asked Questions What is ImmunityBio's current short interest? Short interest is the volume of ImmunityBio shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 54,770,000 shares of IBRX short. 41.52% of ImmunityBio's shares are currently sold short. Learn More on ImmunityBio's current short interest. What is a good short interest ratio for ImmunityBio? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IBRX shares currently have a short interest ratio of 14.0. Learn More on ImmunityBio's short interest ratio. Which institutional investors are shorting ImmunityBio? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunityBio: National Bank of Canada FI, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for ImmunityBio? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 41.52% of ImmunityBio's floating shares are currently sold short. Is ImmunityBio's short interest increasing or decreasing? ImmunityBio saw a increase in short interest in March. As of March 31st, there was short interest totaling 54,770,000 shares, an increase of 2.9% from the previous total of 53,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is ImmunityBio's float size? ImmunityBio currently has issued a total of 677,003,000 shares. Some of ImmunityBio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ImmunityBio currently has a public float of 131,910,000 shares. How does ImmunityBio's short interest compare to its competitors? 41.52% of ImmunityBio's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to ImmunityBio: Iovance Biotherapeutics, Inc. (21.08%), SpringWorks Therapeutics, Inc. (14.45%), Apogee Therapeutics, Inc. (13.11%), Arcellx, Inc. (9.85%), Immunocore Holdings plc (9.49%), Denali Therapeutics Inc. (8.39%), Vericel Co. (9.07%), Immunovant, Inc. (14.92%), TG Therapeutics, Inc. (24.66%), Beam Therapeutics Inc. (16.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short ImmunityBio stock? Short selling IBRX is an investing strategy that aims to generate trading profit from ImmunityBio as its price is falling. IBRX shares are trading down $0.33 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ImmunityBio? A short squeeze for ImmunityBio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IBRX, which in turn drives the price of the stock up even further. How often is ImmunityBio's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBRX, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Iovance Biotherapeutics Short Interest SpringWorks Therapeutics Short Interest Apogee Therapeutics Short Interest Arcellx Short Interest Immunocore Short Interest Denali Therapeutics Short Interest Vericel Short Interest Immunovant Short Interest TG Therapeutics Short Interest Beam Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IBRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press